Hepatitis C New Drugs Review
29.1K views | +6 today
Follow
Hepatitis C New Drugs Review
FDA approved Incivek(telaprevir, Vertex) on Monday 23 May by its PDUFA deadline.A paradigm shift in the treatment of Hepatitis C virus infection. <a href="http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#"; rel="nofollow">http://knol.google.com/k/krishan-maggon/boceprevir-merck-telaprevir-vertex/3fy5eowy8suq3/151#</a>;
Curated by Krishan Maggon
Your new post is loading...
Your new post is loading...
Scooped by Krishan Maggon
Scoop.it!

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"

Created public version #121 of the knol: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval" | Hepatitis C New Drugs Review | Scoop.it
Krishan Maggon published version 121 of a knol titled: "Boceprevir (Merck) & Telaprevir (Vertex) Hepatitis C : FDA Review & Approval"...
more...
Scooped by Krishan Maggon
Scoop.it!

New research aims to help improve uptake of hepatitis C testing

New research aims to help improve uptake of hepatitis C testing | Hepatitis C New Drugs Review | Scoop.it
New research published in Scientific Reports shows persisting fears about HIV infection may impact testing uptake for the hepatitis C Virus (HCV).
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Osteopontin: A new emerging role in HCV-related hepatocellular carcinoma | EurekAlert! Science News

Osteopontin: A new emerging role in HCV-related hepatocellular carcinoma | EurekAlert! Science News | Hepatitis C New Drugs Review | Scoop.it
A research team based in Japan led by Kanazawa University has demonstrated the effect of osteopontin on hepatitis C virus replication and interferon signaling in cancer stem cells. Their research sheds light on a novel therapeutic target for treating hepatocellular carcinoma.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells

Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells | Hepatitis C New Drugs Review | Scoop.it
Plasmacytoid dendritic cells (pDCs) are innate immune cells with high antiviral activity triggered by Toll-like receptor 7 (TLR-7) and TLR-9 stimulation. Moreover, they are important mediators between innate and adaptive immunity.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: an integrated analysis - Serfaty - - Journal of...

European treatment guidelines for hepatitis C virus (HCV) infection recommend that people with genotype (GT)1a infection and baseline viral load ≤800,000 IU/mL receive elbasvir/grazoprevir (EBR/GZR) for 12 weeks, and those with baseline viral load >800,000 IU/mL receive EBR/GZR plus ribavirin for 16 weeks. This analysis was conducted to clarify whether baseline viral load can serve as an accurate, sensitive, or specific stratification factor for defining EBR/GZR regimens. In this post hoc, integrated analysis, participants with GT1a infection who received EBR 50 mg/GZR 100 mg for 12 weeks were stratified according to baseline viral load. Sustained virologic response at 12 weeks post‐treatment was achieved by 95.2% (911/957) of participants, and was higher among participants with baseline viral load ≤800,000 IU/mL versus >800,000 IU/mL (98.5% vs 93.9%). The 800,000 IU/mL threshold had a positive predictive value of 98.5%, a negative predictive value of 6.1%, a specificity of 91.3%, a sensitivity of 28.4%, and an overall accuracy of 31.5%. A baseline viral load cutpoint of 800,000 IU/mL had high positive predictive value and specificity but poor negative predictive value, sensitivity, and accuracy in predicting treatment outcomes in this population. Baseline NS5A resistance‐associated substitutions (RASs) were detected in 25% (1/4) of virologic failures with baseline viral load ≤800,000 IU/mL and 59.5% (25/42) of those with baseline viral load >800,000 IU/mL. Overall, these data suggest that, compared with the use of a baseline viral load cutpoint, baseline testing for NS5A RASs enables more individuals to receive the 12‐week EBR/GZR regimen without compromising the opportunity for SVR.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Synthesis of ABBV-168, a 2’-Bromouridine for the Treatment of Hepatitis C - The Journal of Organic Chemistry (ACS Publications)

Synthesis of ABBV-168, a 2’-Bromouridine for the Treatment of Hepatitis C - The Journal of Organic Chemistry (ACS Publications) | Hepatitis C New Drugs Review | Scoop.it
ABBV-168 is a dihalogenated nucleotide under investigation for the treatment of hepatitis C virus (HCV). Three synthetic routes aimed at achieving the stereoselective installation of the C2' gem-Br,F substitution and subsequent Vorbruggen glycosylation were explored to prepare the penultimate nucleoside intermediate. Development culminated in a route to ABBV-168 featuring a de novo chromatography-free furanose synthesis, protecting group-directed Vorbruggen glycosylation, and highly selective phosphoramidation to furnish the API.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Increasing Hepatitis C Virus Screening in People Who Inject Drugs in Switzerland Using Rapid Antibody Saliva and Dried Blood Spot Testing: a Cost‐Effectiveness Analysis - Girardin - - Journal of Vi...

People who inject drugs (PWID) are a key high‐risk group for HCV infection due to the sharing of needles and drug‐preparation equipment. However, only approximately 50% of PWID are currently screened for HCV in Switzerland. At present, screening of PWID occurs in general practice via venepuncture. Compared to venepuncture, screening via rapid antibody saliva and dried blood spot (DBS) tests is well adapted to PWID, who typically have difficult venous access. The cost‐effectiveness of an increased access screening programme of PWID (increased screening using rapid antibody saliva tests and DBS tests [semi‐quantitative viraemia and viral genotype]) was analysed through a decision tree screening model combined with the outputs of a Markov treatment model. Sensitivity and scenario analyses examined the uncertainty of results. At a willingness to pay (WTP) threshold of CHF 100,000 (USD 105,000) per quality‐adjusted life year (QALY), the increased access screening programme was cost‐effective compared to current screening, with a base case incremental cost‐effectiveness ratio of CHF 7,940 (USD 8,337) per QALY. The net monetary benefit was CHF 959,802,668 (USD 1,007,792,801) for the PWID population, and CHF 94,469 (USD 99,192) per person. The increased access screening programme had a 97.0% probability of being cost‐effective compared to the current screening method at the WTP threshold of CHF 100,000 (USD 105,000).The results showed an increased access screening programme that uses tests which are better‐suited to the PWID population to be more cost‐effective, due to the increased uptake that rapid antibody saliva and DBS tests generate. This article is protected by copyright. All rights reserved.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Microelimination could be a big deal for HCV and HIV services

On October 10, the British HIV Association (BHIVA) announced ambitious targets for
the elimination of hepatitis C virus (HCV) in patients with HIV by 2021: the aim is
to cure HCV in 80% of those co-infected by April 2019, 90% by April 2020, and 100%
by April 2021.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

WHO | Hepatitis B and C virus seroprevalence, Burkina Faso: a cross-sectional study

WHO | Hepatitis B and C virus seroprevalence, Burkina Faso: a cross-sectional study | Hepatitis C New Drugs Review | Scoop.it
abstract published in November 2018...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

The comprehensive outcomes of hepatitis C virus infection: A multi‐faceted chronic disease - Younossi - 2018 - Journal of Viral Hepatitis - Wiley Online Library

The comprehensive outcomes of hepatitis C virus infection: A multi‐faceted chronic disease - Younossi - 2018 - Journal of Viral Hepatitis - Wiley Online Library | Hepatitis C New Drugs Review | Scoop.it
Summary
Treatment of hepatitis C virus (HCV) infection has been revolutionized with the introduction of pangenotypic, interferon‐ and ribavirin‐free regimens associated with high cure rates and a low side effect profile. Additionally, there is evidence that HCV cure reduces HCV complications, improves patient‐reported outcomes and is cost‐saving in most western countries in the long term. This is a review of the comprehensive burden of HCV and the value of eliminating HCV infection. With the introduction of the interferon‐free all‐oral, once a day pill treatment regimen for the cure of HCV, the potential to eliminate HCV by 2030 has become a possibility for some regions of the world. Nevertheless, there are barriers to screening, linkage to care, and treatment in many countries that must be overcome in order to reach this goal. In conclusion, globally, work must continue to ensure national policies are in place to support screening, linkage to care and affordable treatment in order to eliminate HCV.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Safety and Efficacy of Combined Sofosbuvir/Daclatasvir Treatment of Children and Adolescents with Chronic Hepatitis C Genotype 4 - Abdel Ghaffar - - Journal of Viral Hepatitis - Wiley Online Library

Safety and Efficacy of Combined Sofosbuvir/Daclatasvir Treatment of Children and Adolescents with Chronic Hepatitis C Genotype 4 - Abdel Ghaffar - - Journal of Viral Hepatitis - Wiley Online Library | Hepatitis C New Drugs Review | Scoop.it
Direct‐acting antivirals have become available for treating chronic HCV (hepatitis C virus) infection in adults and, recently, in children at least 12 years old. Our aim was to investigate the safety and efficacy of combined sofosbuvir (SOF)/daclatasvir (DCV) for HCV Genotype 4 in children aged 8 to 18 years or weighing 17 kg or more. 40 chronic HCV infected, treatment‐naïve children with well compensated livers were recruited from two sites. Patients received combined therapy of SOF (400 mg/day for patients weighing greater than 45 kg; 200 mg/day for patients weighing 17 to 45 kg) and DCV (60 mg/day for patients weighing greater than 45 kg; 30 mg/day for patients weighing 17 to 45 kg) for 12 weeks. They were followed up regularly by clinical examination and laboratory tests during treatment (weekly in the first month then monthly to the end of treatment), every three months for 6 months post‐treatment, and at 48 weeks post‐treatment. In our cohort, which included 45% of children below the age of 12 years (72.5% genotype 4 and 27.5% mixed genotype 4 and 1), end of treatment response (ETR) was 97.5%. Sustained virologic response for weeks 12 and 24 post treatment (SVR12 and SVR24) were 97.5% and 95% respectively on an intention to treat basis, and 100% and 100% for those who completed the study protocol. Observed side‐effects were mild and none required drug cessation. Combined SOF/DCV was found to be effective and safe for treating HCV Genotype 4 infected children, 8 years of age and above. This article is protected by copyright. All rights reserved.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Hepatitis C Prevalence Estimates 2013-2016 | 2018 | Newsroom | NCHHSTP | CDC

Hepatitis C Prevalence Estimates 2013-2016 | 2018 | Newsroom | NCHHSTP | CDC | Hepatitis C New Drugs Review | Scoop.it
CDC Estimates Nearly 2.4 Million Americans Living with Hepatitis C...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir

Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir | Hepatitis C New Drugs Review | Scoop.it
In our study, we observed the dynamic changes of natural killer (NK) cell subsets, phenotypes and functional parameters during and after direct-acting antivirals (DAAs) treatment and investigated the effect of sofosbuvir/ledipasvir therapy on innate immunity in genotype 1b hepatitis C virus (HCV)-infected patients. We illustrated that NK cells of chronic hepatitis C patients can be affected by DAAs and phenotypes and function of NK cells recovered not at early stage but mainly after the end of sofosbuvir/ledipasvir treatment. These findings may provide an explanation for HCV reinfection or liver carcinogenesis after HCV elimination.

Citation: Wang XX, Luo BF, Jiang HJ, Cong X, Jin Q, Ma DL, Wei L, Feng B. Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir. World J Gastroenterol 2018; 24(40): 4554-4564
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Transgene - Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune respons...

Transgene - Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune respons... | Hepatitis C New Drugs Review | Scoop.it
Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice

 

TG1050 is a targeted immunotherapy candidate for the treatment of chronic hepatitis B, based on a viral vector expressing three HBV antigens. Transgene has conducted a randomized, multi-center, double-blind, placebo-controlled safety and dose-finding first-in-humans study (NCT02428400) evaluating the safety and tolerability of TG1050 in patients who are currently being treated for chronic HBV infection with standard-of-care antiviral therapy. First results were announced at AASLD in 2017, confirming the satisfying tolerability of TG1050 in the first cohort, as well as confirming the product’s mechanism of action.

Pre-clinical results have demonstrated TG1050’s capacity to induce robust, broad and long-lasting HBV-specific T cells with characteristics similar to those found in patients whose infection is resolved. Antiviral effects of TG1050, including seroconversion to the surface antigen (HBsAg), have also been shown.

more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients

No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients | Hepatitis C New Drugs Review | Scoop.it
Chronic hepatitis C virus infection (HCV) is a global health problem causing death and morbidity.1 Recent studies have shown that the global prevalence of HCV is estimated to be 1% in 2015, corresponding to 71.1 million individuals with chronic HCV infection.2,3 The disease burden of HCV infection...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Glecaprevir/Pibrentasvir Demonstrates SVR in Treatment-Naive Patients with Hepatitis C Virus and Compensated Cirrhosis

Glecaprevir/Pibrentasvir Demonstrates SVR in Treatment-Naive Patients with Hepatitis C Virus and Compensated Cirrhosis | Hepatitis C New Drugs Review | Scoop.it
At 12 weeks post treatment per protocol analysis with 8 weeks of glecaprevir/pibrentasvir treatment, patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4

Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4 | Hepatitis C New Drugs Review | Scoop.it
Abstract
In adults, treatment of hepatitis C virus (HCV) infection with ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) with or without dasabuvir (DSV) and ±ribavirin (RBV) results in high rates of sustained virologic response (SVR). However, these regimens have not been investigated in adolescents. This ongoing, open‐label, phase 2/3 study evaluated the pharmacokinetics, safety, and efficacy of OBV/PTV/r+DSV±RBV treatment for 12 weeks in adolescents infected with HCV genotype (GT) 1 without cirrhosis (part 1) and the safety and efficacy of OBV/PTV/r±DSV±RBV treatment for 12 or 24 weeks in adolescents infected with GT1 or GT4 without cirrhosis or with compensated cirrhosis (parts 1 and 2). Patients were 12‐17 years of age and treatment naive or interferon experienced. Treatment regimens were based on HCV GT and cirrhosis status. Endpoints were SVR at posttreatment week 12 (SVR12), adverse events (AEs), and pharmacokinetic parameters. Thirty‐eight adolescents were enrolled, 66% were female patients, and 76% were White; 42%, 40%, and 18% of patients had HCV GT1a, GT1b, and GT4 infections, respectively. Median age was 15 years (range, 12‐17 years), and 1 patient had cirrhosis. The SVR12 rate was 100% (38/38; 95% confidence interval [CI], 90.8%‐100%). No treatment‐emergent grade 3 or 4 laboratory abnormalities were reported. No serious AEs occurred on treatment, and no AEs led to study drug discontinuation. The most common AEs were headache (21%), fatigue (18%), nasopharyngitis (13%), pruritus (13%), and upper respiratory tract infection (11%). Intensive pharmacokinetic results showed OBV, PTV, DSV, and ritonavir drug exposures were comparable to those seen in adults. Conclusion: Treatment with OBV/PTV/r±DSV±RBV was well tolerated and highly efficacious in adolescents with HCV GT1 or GT4 infection.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community

Comparison of FIB-4 and transient elastography in evaluating liver fibrosis of chronic hepatitis C subjects in community | Hepatitis C New Drugs Review | Scoop.it
Background and aim The role of non-invasive methods to evaluate fibrosis severity of chronic hepatitis C (CHC) subjects in community needs to be explored. This study investigated FIB-4 and transient elastography (TE) in staging liver fibrosis of CHC subjects in community. Methods A total of 905 subjects who were positive for anti-HCV antibody from five districts of Tainan City of Taiwan were invited to participate in surveillance activities for CHC. FIB-4 and TE were measured for each participant. Results A total of 502 subjects with detectable HCV RNA and valid TE were enrolled. The distribution of FIB-4 and TE values differed markedly. Both methods exhibited a strongest correlation in subjects with at age 50~60 years (r = 0.655, p <0.001). FIB-4 score increased proportionally with age (p <0.001), but TE did not (p = 0.142). The intraclass correlation efficient of both methods was 0.255 (p <0.001). Subjects with TE defined advanced fibrosis exhibited younger age, higher BMI, higher platelet count, lower FIB-4 score, higher incidence of fatty liver and splenomegaly, and higher controlled attenuation parameter value than those defined by FIB-4. By multivariate logistic regression analysis, higher ALT levels, higher incidence of fatty liver, and presence of splenomegaly were the independent factors associated with advanced fibrosis defined by TE rather than defined by FIB-4. Conclusions FIB-4 and TE defined different distribution of fibrosis stages in same HCV population. FIB-4 was deeply influenced by age whereas TE was not. TE had the advantages over than FIB-4 in strong association with splenomegaly and in detecting the role of non-alcoholic fatty liver disease in advanced fibrosis.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Prediction of Liver Disease, AIDS, and Mortality Based on Discordant Absolute and Relative Peripheral CD4 T Lymphocytes in HIV/Hepatitis C Virus-Co...

Prediction of Liver Disease, AIDS, and Mortality Based on Discordant Absolute and Relative Peripheral CD4 T Lymphocytes in HIV/Hepatitis C Virus-Co... | Hepatitis C New Drugs Review | Scoop.it
A new interesting article has been published in AIDS Res Hum Retroviruses. 2018 Oct 23. doi: 10.1089/AID.2017.0058.[Epub ahead of print] and titled: Prediction of Liver Disease, AIDS, and Mortality Based on …...
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Exploring NS3/4A, NS5A and NS5B proteins to design conserved subunit multi-epitope vaccine against HCV utilizing immunoinformatics approaches

Exploring NS3/4A, NS5A and NS5B proteins to design conserved subunit multi-epitope vaccine against HCV utilizing immunoinformatics approaches | Hepatitis C New Drugs Review | Scoop.it
Hepatitis C virus (HCV) vaccines, designed to augment specific T-cell responses, have been designated as an important aspect of effective antiviral treatment. However, despite the current satisfactory progress of these vaccines, extensive past efforts largely remained unsuccessful in mediating clinically relevant anti-HCV activity in humans. In this study, we used a series of immunoinformatics approaches to propose a multiepitope vaccine against HCV by prioritizing 16 conserved epitopes from three viral proteins (i.e., NS34A, NS5A, and NS5B). The prioritised epitopes were tested for their possible antigenic combinations with each other along with linker AAY using structural modelling and epitope–epitope interactions analysis. An adjuvant (β-defensin) at the N-terminal of the construct was added to enhance the immunogenicity of the vaccine construct. Molecular dynamics (MD) simulation revealed the most stable structure of the proposed vaccine. The designed vaccine is potentially antigenic in nature and can form stable and significant interactions with Toll-like receptor 3 and Toll-like receptor 8. The proposed vaccine was also subjected to an in silico cloning approach, which confirmed its expression efficiency. These analyses suggest that the proposed vaccine can elicit specific immune responses against HCV; however, experimental validation is required to confirm the safety and immunogenicity profile of the proposed vaccine construct.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Quasispecies of Hepatitis C Virus Participate in Cell-Specific Infectivity

Quasispecies of Hepatitis C Virus Participate in Cell-Specific Infectivity | Hepatitis C New Drugs Review | Scoop.it
Abstract
It is well documented that a variety of viral quasispecies are found in the patients with chronic infection of hepatitis C virus (HCV). However, the significance of quasispecies in the specific infectivity to individual cell types remains unknown. In the present study, we analyzed the role of quasispecies of the genotype 2a clone, JFH1 (HCVcc), in specific infectivity to the hepatic cell lines, Huh7.5.1 and Hep3B. HCV RNA was electroporated into Huh7.5.1 cells and Hep3B/miR-122 cells expressing miR-122 at a high level. Then, we adapted the viruses to Huh7 and Hep3B/miR-122 cells by serial passages and termed the resulting viruses HCVcc/Huh7 and HCVcc/Hep3B, respectively. Interestingly, a higher viral load was obtained in the homologous combination of HCVcc/Huh7 in Huh7.5.1 cells or HCVcc/Hep3B in Hep3B/miR-122 cells compared with the heterologous combination. By using a reverse genetics system and deep sequence analysis, we identified several adaptive mutations involved in the high affinity for each cell line, suggesting that quasispecies of HCV participate in cell-specific infectivity.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013‐2016 - Hofmeister - - Hepatology - Wiley Online Library

Estimating Prevalence of Hepatitis C Virus Infection in the United States, 2013‐2016 - Hofmeister - - Hepatology - Wiley Online Library | Hepatitis C New Drugs Review | Scoop.it
Hepatitis C virus (HCV) infection is the most commonly reported bloodborne infection in the United States, causing substantial morbidity and mortality and costing billions of dollars annually. To update the estimated HCV prevalence among all adults aged ≥18 years in the United States, we analyzed 2013‐2016 data from the National Health and Nutrition Examination Survey (NHANES) to estimate the prevalence of HCV in the noninstitutionalized civilian population and used a combination of literature reviews and population size estimation approaches to estimate the HCV prevalence and population sizes for four additional populations: incarcerated people, unsheltered homeless people, active‐duty military personnel, and nursing home residents. We estimated that during 2013‐2016 1.7% (95% confidence interval [CI], 1.4‐2.0%) of all adults in the United States, approximately 4.1 (3.4‐4.9) million persons, were HCV antibody‐positive (indicating past or current infection) and that 1.0% (95% CI, 0.8‐1.1%) of all adults, approximately 2.4 (2.0‐2.8) million persons, were HCV RNA–positive (indicating current infection). This includes 3.7 million noninstitutionalized civilian adults in the United States with HCV antibodies and 2.1 million with HCV RNA and an estimated 0.38 million HCV antibody‐positive persons and 0.25 million HCV RNA–positive persons not part of the 2013‐2016 NHANES sampling frame. Conclusion: Over 2 million people in the United States had current HCV infection during 2013‐2016; compared to past estimates based on similar methodology, HCV antibody prevalence may have increased, while RNA prevalence may have decreased, likely reflecting the combination of the opioid crisis, curative treatment for HCV infection, and mortality among the HCV‐infected population; efforts on multiple fronts are needed to combat the evolving HCV epidemic, including increasing capacity for and access to HCV testing, linkage to care, and cure.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

CDC Estimates Nearly 2.4 Million Americans Living with Hepatitis C

CDC Estimates Nearly 2.4 Million Americans Living with Hepatitis C | Hepatitis C New Drugs Review | Scoop.it
This press release describes the findings in the release of Hepatitis C Prevalence Estimates 2013-2016 including graphics, infographics, and quotes from subject matter experts.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape

HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape | Hepatitis C New Drugs Review | Scoop.it
Regimens based on direct-acting antivirals (DAAs) have revolutionized treatment of
patients with chronic infection with hepatitis C virus (HCV), which globally has been
estimated to cause 70-150 million chronic infections and at least 400.000 annual deaths[1,2].
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial | Hepatitis C New Drugs Review | Scoop.it
Glecaprevir/pibrentasvir achieved high SVR12 rates, comparable with data reported in registrational studies, and was well tolerated in patients with HCV genotype 5 or 6 infection with compensated liver disease.
Funding
AbbVie.
more...
No comment yet.
Scooped by Krishan Maggon
Scoop.it!

Successful DAA Treatment and Global Improvement in a Cirrhotic Patient with Concomitant HCV Infection and Autoimmune Hepatitis

Successful DAA Treatment and Global Improvement in a Cirrhotic Patient with Concomitant HCV Infection and Autoimmune Hepatitis | Hepatitis C New Drugs Review | Scoop.it
Hepatitis C virus (HCV) infection has been linked to the development of autoimmunity, in part through activation of B cells, which also plays a pathogenic role in autoimmune diseases of the liver [1]. Since excessive immune response against HCV may promote autoimmunity, it is reasonable to consider this added benefit of HCV eradication by direct-acting antiviral (DAA), although there may be concerns related to recent reports of DAA-induced AIH in patients treated for HCV [2]. Here, we describe the case of a patient with chronic HCV infection and AIH who was successfully treated with DAA, and who showed a considerable improvement in global liver function after viral clearance.
more...
No comment yet.